Halozyme Therapeutics, Inc.
HALOBiotechnology
$131.18+0.88%As of Oct 29vs prior close
- Market cap
- $14.9B
- P/E (TTM)
- 37.0×
- P/E (FY1)
- 14.8×
- From 52W high
- 0.00%
- EPS (LTM)
- $3.42
- Revenue (LTM)
- $1.7B
- Net margin
- 24.86%
- Dividend yield
- 0.00%
Nomior Score
88
Vanguard CompounderTop 1% of the scored universe
Growth67
Quality86
Value63
Momentum91
Resilience55
Growth
+28.45%revenue a year over 9 fiscal years
YE16 $146.7MLTM $1.7B
Connections
Revenue to profitQ2 YE26
48% of revenue became net profit, down 3 pts on a year.
Who owns it
2funds, 1 tracked portfolio